江苏生物医药集群发明专利拥有量全国第一

Core Insights - Jiangsu's biopharmaceutical cluster is projected to have 46,200 invention patents by July 2025, ranking first in the nation [1] - The provincial intellectual property office and medical security bureau have issued a notice to enhance intellectual property protection in the pharmaceutical procurement sector, aiming for balanced development between innovative and generic drugs [1] Group 1: Intellectual Property Protection Measures - A comprehensive "commitment-verification-disposal" mechanism will be established to prevent and resolve patent disputes in pharmaceutical procurement [1] - The notice outlines three key initiatives: establishing a source commitment system to strengthen corporate responsibility, creating a rapid response system to improve dispute resolution efficiency, and enhancing collaborative regulatory mechanisms for long-term protection [1] Group 2: Establishment of Support Structures - Jiangsu will set up a provincial intellectual property technical investigation center to provide professional judgment support for patent infringement disputes in pharmaceutical procurement [2] - An administrative adjudication fast track will be established to simplify trial procedures and reduce case resolution time, while encouraging parties to resolve disputes through self-negotiation or administrative mediation [2] - Joint actions against patent infringement will be strengthened, including measures like network removal and disqualification from selection, to create a regulatory loop of "information sharing-professional judgment-rapid disposal" [2]